Eradication Therapy for Helicobacter pylori with Diagnostic Test for Clarithromycin Resistance
- Author:
Yeon Ji KIM
1
;
Woo Chul CHUNG
Author Information
- Publication Type:Review
- Keywords: Clarithromycin; Drug resistance; Eradication; Helicobacter pylori
- MeSH: Clarithromycin; Diagnostic Tests, Routine; Drug Resistance; Drug Resistance, Microbial; Helicobacter pylori; Helicobacter; Humans; Point Mutation; RNA, Ribosomal, 23S
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2019;19(4):225-230
- CountryRepublic of Korea
- Language:Korean
- Abstract: Addressing the increasing antibiotic resistance, including clarithromycin resistance, which affects Helicobacter pylori (H. pylori) eradication therapy, is a challenge for clinicians. Antibiotic resistance is the main reason for H. pylori eradication failure and the resistance rate for clarithromycin may drastically increase, up to 38.5%, due to 23S ribosomal RNA point mutations. Therefore, the standard triple regimen is no longer suitable as the first-line treatment in most regions. However, there is a growing interest in personalized care for patients. Increased eradication rates of tailored therapy based on antibiotic susceptibility have been reported using nucleic acid-based techniques for clarithromycin resistance with a focus on the first-line eradication therapy of H. pylori infection. Herein, we discuss the eradication therapy for H. pylori, with a diagnostic test and appropriate treatment for clarithromycin resistance.
